Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FOS | P01100 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530643 | 0.99 | MEN1 (0.50) | KMT2AMEN1CSF1RALDH1A1MAPT | |
| SCHEMBL10991468 | 0.86 | RAB9A (0.42) | KMT2AMEN1CSF1RALDH1A1MAPT | |
| SCHEMBL3293567 | 0.83 | NPC1 (0.43) | KMT2ACSF1RALDH1A1MAPTPDE4B | |
| SCHEMBL3532297 | 0.82 | ALDH1A1 (0.43) | KMT2ACSF1RALDH1A1MAPTPOLB | |
| SCHEMBL10987423 | 0.81 | ADRB2 (0.42) | KMT2ACSF1RALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11582898 | 0.80 | SMN1; SMN2 (0.53) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3291298 | 0.80 | CSF1R (0.50) | CSF1RALDH1A1 | |
| SCHEMBL10993730 | 0.79 | CASP1 (0.55) | KMT2AMEN1CSF1RMAPTPOLB | |
| SCHEMBL3292270 | 0.78 | CSF1R (0.56) | CSF1R | |
| SCHEMBL3293197 | 0.78 | CSF1R (0.49) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728003-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-01 | — | — | US | disclosed |
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| EP-1945637-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1937681-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
| WO-2008055013-A2 | 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007033232-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033137-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060578-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | FLT3, FES, ALK | KMT2A 2689/4885MEN1 3558/4885CSF1R 430/4885 |
| US-20070060578-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | KMT2A 1544/4885MEN1 3185/4885CSF1R 598/4885 |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | KMT2A 1844/4885MEN1 3337/4885CSF1R 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.